The 90 kDa ribosomal S6 kinase (RSK) household of proteins is a gaggle of extremely conserved Ser/Thr kinases that regulate various mobile processes, resembling cell progress, cell motility, cell survival and cell proliferation. RSKs are downstream effectors of the Ras-extramobile signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signalling cascade.
Important advances within the subject of RSK and ERK/MAPK signalling have occurred prior to now few years, together with organic insights and the invention of novel substrates and new RSK regulatory mechanisms. Collectively, these information broaden the present fashions of RSK signalling and spotlight potential instructions of analysis in RSK-mediated survival, progress, proliferation and migration.
Transgenerational epigenetic inheritance: prevalence, mechanisms, and implications for the research of heredity and evolution.
This assessment describes new developments within the research of transgenerational epigenetic inheritance, a element of epigenetics. We begin by analyzing the essential ideas of the sector and the mechanisms that underlie epigenetic inheritance. We current a complete assessment of transgenerational mobile epigenetic inheritance amongst completely different taxa within the type of a desk, and focus on the information contained therein.
The evaluation of those information exhibits that epigenetic inheritance is ubiquitous and suggests strains of analysis that transcend current approaches to the topic. We conclude by exploring a number of the penalties of epigenetic inheritance for the research of evolution, whereas additionally pointing to the significance of recognizing and understanding epigenetic inheritance for sensible and theoretical points in biology.
Rules for characterizing the potential human well being results from publicity to nanomaterials: components of a screening technique.
The speedy proliferation of many various engineered nanomaterials (outlined as supplies designed and produced to have structural options with no less than one dimension of 100 nanometers or much less) presents a dilemma to regulators concerning hazard identification.
The Worldwide Life Sciences Institute Analysis Basis/Danger Science Institute convened an professional working group to develop a screening technique for the hazard identification of engineered nanomaterials. The working group report presents the weather of a screening technique somewhat than an in depth testing protocol. Primarily based on an analysis of the restricted information at the moment accessible, the report presents a broad information gathering technique relevant to this early stage within the improvement of a threat evaluation course of for nanomaterials.
Oral, dermal, inhalation, and injection routes of publicity are included recognizing that, relying on use patterns, publicity to nanomaterials might happen by any of those routes. The three key components of the toxicity screening technique are: Physicochemical Traits, In Vitro Assays (mobile and non-mobile), and In Vivo Assays. There’s a robust probability that organic exercise of nanoparticles will rely on physicochemical parameters not routinely thought-about in toxicity screening research.
Physicochemical properties which may be essential in understanding the poisonous results of take a look at supplies embody particle measurement and measurement distribution, agglomeration state, form, crystal construction, chemical composition, floor space, floor chemistry, floor cost, and porosity. In vitro strategies permit particular organic and mechanistic pathways to be remoted and examined underneath managed circumstances, in methods that aren’t possible in in vivo exams.
Checks are prompt for portal-of-entry toxicity for lungs, pores and skin, and the mucosal membranes, and goal organ toxicity for endothelium, blood, spleen, liver, nervous system, coronary heart, and kidney. Non-mobile evaluation of nanoparticle sturdiness, protein interactions, complement activation, and pro-oxidant exercise can also be thought-about.
Tier 1 in vivo assays are proposed for pulmonary, oral, pores and skin and injection exposures, and Tier 2 evaluations for pulmonary exposures are additionally proposed. Tier 1 evaluations embody markers of irritation, oxidant stress, and cell proliferation in portal-of-entry and chosen distant organs and tissues.
Tier 2 evaluations for pulmonary exposures may embody deposition, translocation, and toxicokinetics and biopersistence research; results of a number of exposures; potential results on the reproductive system, placenta, and fetus; different animal fashions; and mechanistic research.
Subtypes of medulloblastoma have distinct developmental origins.
Medulloblastoma encompasses a group of clinically and molecularly various tumour subtypes that collectively comprise the most typical malignant childhood mind tumour. These tumours are thought to come up throughout the cerebellum, with roughly 25% originating from granule neuron precursor cells (GNPCs) after aberrant activation of the Sonic Hedgehog pathway (hereafter, SHH subtype).
The pathological processes that drive heterogeneity among the many different medulloblastoma subtypes are usually not recognized, hindering the event of a lot wanted new therapies. Right here we offer proof {that a} discrete subtype of medulloblastoma that incorporates activating mutations within the WNT pathway effector CTNNB1 (hereafter, WNT subtype) arises exterior the cerebellum from cells of the dorsal brainstem.
We discovered that genes marking human WNT-subtype medulloblastomas are extra continuously expressed within the decrease rhombic lip (LRL) and embryonic dorsal brainstem than within the higher rhombic lip (URL) and growing cerebellum. Magnetic resonance imaging (MRI) and intra-operative studies confirmed that human WNT-subtype tumours infiltrate the dorsal brainstem, whereas SHH-subtype tumours are situated throughout the cerebellar hemispheres.
Activating mutations in Ctnnb1 had little influence on progenitor cell populations within the cerebellum, however induced the irregular accumulation of cells on the embryonic dorsal brainstem which included aberrantly proliferating Zic1(+) precursor cells.
These lesions endured in all mutant grownup mice; furthermore, in 15% of circumstances wherein Tp53 was concurrently deleted, they progressed to type medulloblastomas that recapitulated the anatomy and gene expression profiles of human WNT-subtype medulloblastoma.
We offer the primary proof, to our information, that subtypes of medulloblastoma have distinct mobile origins. Our information present an evidence for the marked molecular and medical variations between SHH- and WNT-subtype medulloblastomas and have profound implications for future analysis and therapy of this essential childhood most cancers.
A complete classification system for lipids.
Lipids are produced, transported, and acknowledged by the concerted actions of quite a few enzymes, binding proteins, and receptors. A complete evaluation of lipid molecules, “lipidomics,” within the context of genomics and proteomics is essential to understanding mobile physiology and pathology; consequently, lipid biology has change into a serious analysis goal of the postgenomic revolution and programs biology.
To facilitate worldwide communication about lipids, a complete classification of lipids with a standard platform that’s appropriate with informatics necessities has been developed to take care of the large quantities of information that might be generated by our lipid neighborhood.
As an preliminary step on this improvement, we divide lipids into eight classes (fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids, and polyketides) containing distinct courses and subclasses of molecules, devise a standard method of representing the chemical constructions of particular person lipids and their derivatives, and supply a 12 digit identifier for every distinctive lipid molecule.
 CD134 |
|||
| MO134CFB(V100) | ImmunoStep | 100 ug | EUR 60 |
CD134 |
|||
| MO134CFB(V25) | ImmunoStep | 25 ug | EUR 60 |
CD134 |
|||
| MO134F(V100) | ImmunoStep | 100 ug | EUR 60 |
CD134 |
|||
| MO134F(V25) | ImmunoStep | 25 ug | EUR 60 |
CD134 |
|||
| MO134F(V500) | ImmunoStep | 500 ug | EUR 60 |
CD134 |
|||
| MO134PE(V100) | ImmunoStep | 100 ug | EUR 60 |
CD134 |
|||
| MO134PE(V25) | ImmunoStep | 25 ug | EUR 60 |
CD134 |
|||
| MO134PP(V100) | ImmunoStep | 100 ug | EUR 60 |
CD134 |
|||
| MO134PP(V25) | ImmunoStep | 25 ug | EUR 60 |
CD134 |
|||
| MO134PP5.5(V100) | ImmunoStep | 100 ug | EUR 60 |
CD134 |
|||
| MO134PP5.5(V25) | ImmunoStep | 25 ug | EUR 60 |
CD134 |
|||
| MO134PU(V100) | ImmunoStep | 100 ug | EUR 60 |
CD134 |
|||
| MO134PU(V500) | ImmunoStep | 500 ug | EUR 60 |
 CD134/OX40 |
|||
| MBS8564766-01mL | MyBiosource | 0.1mL | EUR 345 |
CD134/OX40 |
|||
| MBS8564766-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
CD134/OX40 |
|||
| MBS8564766-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
CD134/OX40 |
|||
| MBS8564766-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
CD134/OX40 |
|||
| MBS8564766-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
CD134/OX40 |
|||
| MBS8564767-01mL | MyBiosource | 0.1mL | EUR 345 |
CD134/OX40 |
|||
| MBS8564767-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
CD134/OX40 |
|||
| MBS8564767-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
CD134/OX40 |
|||
| MBS8564767-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
CD134/OX40 |
|||
| MBS8564767-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
 CD134 Antibody |
|||
| 45130-100ul | SAB | 100ul | EUR 302.4 |
CD134 Antibody |
|||
| 45130-50ul | SAB | 50ul | EUR 224.4 |
CD134 Antibody |
|||
| ABD7751 | Lifescience Market | 100 ug | EUR 525.6 |
CD134 Antibody |
|||
| abx140447-100g | Abbexa | 100 µg | EUR 400 |
CD134 Antibody |
|||
| abx140447-100tests | Abbexa | 100 tests | EUR 577.2 |
CD134 Antibody |
|||
| abx140448-100g | Abbexa | 100 µg | EUR 350 |
CD134 Antibody |
|||
| abx140448-100tests | Abbexa | 100 tests | EUR 510 |
CD134 Antibody |
|||
| GWB-96FE7E | GenWay Biotech | 0.1 mg | Ask for price |
CD134 Antibody |
|||
| GWB-687738 | GenWay Biotech | 0.1 mg | Ask for price |
CD134 Antibody |
|||
| E10-31362 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
CD134 Antibody |
|||
| E10-31363 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
CD134 Antibody |
|||
| E38PA4280 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
CD134 Antibody |
|||
| E19-7751-1 | EnoGene | 50ug/50ul | EUR 145 |
|
Description: Available in various conjugation types. |
|||
CD134 Antibody |
|||
| E19-7751-2 | EnoGene | 100ug/100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
CD134 Antibody |
|||
| MBS9608328-01mL | MyBiosource | 0.1mL | EUR 260 |
CD134 Antibody |
|||
| MBS9608328-02mL | MyBiosource | 0.2mL | EUR 305 |
CD134 Antibody |
|||
| MBS9608328-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
CD134 Antibody |
|||
| MBS8582420-01mL | MyBiosource | 0.1mL | EUR 305 |
CD134 Antibody |
|||
| MBS8582420-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
CD134 Antibody |
|||
| MBS8582420-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
CD134 Antibody |
|||
| MBS8582420-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
CD134 Antibody |
|||
| MBS8582420-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
CD134 Antibody |
|||
| MBS8517125-005mg | MyBiosource | 0.05mg | EUR 235 |
CD134 Antibody |
|||
| MBS8517125-01mg | MyBiosource | 0.1mg | EUR 305 |
CD134 Antibody |
|||
| MBS8517125-01mLAF405M | MyBiosource | 0.1mL(AF405M) | EUR 465 |
CD134 Antibody |
|||
| MBS8517125-01mLAF546 | MyBiosource | 0.1mL(AF546) | EUR 465 |
CD134 Antibody |
|||
| MBS8517125-01mLAF750 | MyBiosource | 0.1mL(AF750) | EUR 465 |
 OX-40/CD134 |
|||
| MBS370316-INQUIRE | MyBiosource | INQUIRE | Ask for price |
 (PE)) CD134 (OX40) (PE) |
|||
| MBS6251432-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (PE) |
|||
| MBS6251432-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
 (AP)) CD134 (OX40) (AP) |
|||
| MBS6247471-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (AP) |
|||
| MBS6247471-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
 (HRP)) CD134 (OX40) (HRP) |
|||
| MBS6250411-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (HRP) |
|||
| MBS6250411-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
 (APC)) CD134 (OX40) (APC) |
|||
| MBS6268329-01mL | MyBiosource | 0.1mL | EUR 995 |
CD134 (OX40) (APC) |
|||
| MBS6268329-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
 (FITC)) CD134 (OX40) (FITC) |
|||
| MBS6249499-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (FITC) |
|||
| MBS6249499-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
 CD134 Rabbit pAb |
|||
| A24523 | Abclonal | 20μL | EUR 152.33 |
 CD134 Rabbit mAb |
|||
| 56422 | SAB | 100ul | EUR 339 |
CD134 Rabbit mAb |
|||
| E38A1018 | EnoGene | 100ug/100ul | EUR 255 |
CD134 Rabbit pAb |
|||
| E47R2685 | EnoGene | 100ul | EUR 295 |
) CD134, Mouse (OX40) |
|||
| MBS4381531-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
CD134, Mouse (OX40) |
|||
| MBS4381531-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
CD134, Mouse (OX40) |
|||
| MBS4381531-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
CD134, Mouse (OX40) |
|||
| MBS4381531-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
CD134, Mouse (OX40) |
|||
| MBS4381531-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
 CD134/OX40 ELISA |
|||
| MBS495682-5x96Tests | MyBiosource | 5x96Tests | EUR 4655 |
CD134/OX40 ELISA |
|||
| MBS495682-96Tests | MyBiosource | 96Tests | EUR 1005 |
CD134 Rabbit pAb |
|||
| MBS8543698-01mL | MyBiosource | 0.1mL | EUR 305 |
CD134 Rabbit pAb |
|||
| MBS8543698-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
CD134 Rabbit pAb |
|||
| MBS8543698-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
CD134 Rabbit pAb |
|||
| MBS8543698-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
CD134 Rabbit pAb |
|||
| MBS8543698-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
) CD134 Antibody (PE) |
|||
| abx229303-100g | Abbexa | 100 µg | EUR 162.5 |
CD134 Antibody (PE) |
|||
| GWB-51D857 | GenWay Biotech | 100 TESTS | Ask for price |
 (Biotin)) CD134 (OX40) (Biotin) |
|||
| MBS6248503-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (Biotin) |
|||
| MBS6248503-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
(Biotin)) CD134 (OX40)(Biotin) |
|||
| MBS6507234-005mg | MyBiosource | 0.05mg | EUR 1005 |
CD134 (OX40)(Biotin) |
|||
| MBS6507234-5x005mg | MyBiosource | 5x0.05mg | EUR 4375 |
) CD134 Antibody (APC) |
|||
| abx229304-100g | Abbexa | 100 µg | EUR 100 |
 Rat CD134 Antibody |
|||
| GWB-E27EEF | GenWay Biotech | 0.1 mg | Ask for price |
 Cat CD134 Antibody |
|||
| GWB-B3EA66 | GenWay Biotech | 0.1 mg | Ask for price |
Rat CD134 Antibody |
|||
| GWB-F24359 | GenWay Biotech | 0.25 mg | Ask for price |
Cat CD134 Antibody |
|||
| GWB-5A2C6C | GenWay Biotech | 0.25 mg | Ask for price |
 OX40/CD134/TNFRSF4 |
|||
| MBS556150-01mL | MyBiosource | 0.1mL | EUR 455 |
OX40/CD134/TNFRSF4 |
|||
| MBS556150-5x01mL | MyBiosource | 5x0.1mL | EUR 1895 |
OX40/CD134/TNFRSF4 |
|||
| MO47051 | Neuromics | 100 ul | EUR 278.1 |
) CD134 Antibody (FITC) |
|||
| 20-abx200691 | Abbexa |
|
|
CD134 Antibody (FITC) |
|||
| abx229302-100g | Abbexa | 100 µg | EUR 100 |
CD134 Antibody (FITC) |
|||
| GWB-5DD6A2 | GenWay Biotech | 0.1 mg | Ask for price |
 CD134/OX40 Antibody |
|||
| E8EM1701-24 | EnoGene | 100ul | EUR 275 |
|
Description: Available in various conjugation types. |
|||
CD134/OX40 Antibody |
|||
| E8EM1701-25 | EnoGene | 100ul | EUR 275 |
|
Description: Available in various conjugation types. |
|||
 Mouse CD134 Antibody |
|||
| GWB-ED2B06 | GenWay Biotech | 0.02 mg | Ask for price |
Mouse CD134 Antibody |
|||
| GWB-7FFB78 | GenWay Biotech | 0.1 mg | Ask for price |
Mouse CD134 Antibody |
|||
| GWB-838D6E | GenWay Biotech | 0.25 mg | Ask for price |
) CD134 Antibody (Biotin) |
|||
| 20-abx200689 | Abbexa |
|
|
CD134 Antibody (Biotin) |
|||
| GWB-93423D | GenWay Biotech | 0.1 mg | Ask for price |
 CD134 Blocking Peptide |
|||
| 20-abx161491 | Abbexa |
|
|
CD134 Blocking Peptide |
|||
| 20-abx161492 | Abbexa |
|
|
 TNFRSF4/CD134 Antibody |
|||
| DF7751 | Affbiotech | 200ul | EUR 420 |
TNFRSF4/CD134 Antibody |
|||
| DF7751-100ul | Affinity Biosciences | 100ul | EUR 168 |
|
Description: WB,IHC,ELISA(peptide) |
|||
TNFRSF4/CD134 Antibody |
|||
| DF7751-200ul | Affinity Biosciences | 200ul | EUR 210 |
|
Description: WB,IHC,ELISA(peptide) |
|||
CD134 Blocking Peptide |
|||
| DF7751-BP | Affbiotech | 1mg | EUR 234 |
TNFRSF4/CD134 Antibody |
|||
| DF7812 | Affbiotech | 200ul | EUR 420 |
TNFRSF4/CD134 Antibody |
|||
| DF7812-100ul | Affinity Biosciences | 100ul | EUR 168 |
|
Description: WB,ELISA(peptide) |
|||
TNFRSF4/CD134 Antibody |
|||
| DF7812-200ul | Affinity Biosciences | 200ul | EUR 210 |
|
Description: WB,ELISA(peptide) |
|||
CD134 Blocking Peptide |
|||
| MBS8240078-1mg | MyBiosource | 1mg | EUR 190 |
CD134 Blocking Peptide |
|||
| MBS8240078-5mg | MyBiosource | 5mg | EUR 345 |
CD134 Blocking Peptide |
|||
| MBS8240078-5x5mg | MyBiosource | 5x5mg | EUR 1465 |
CD134 Blocking Peptide |
|||
| MBS8204460-1mg | MyBiosource | 1mg | EUR 190 |
CD134 Blocking Peptide |
|||
| MBS8204460-5mg | MyBiosource | 5mg | EUR 345 |
CD134 Blocking Peptide |
|||
| MBS8204460-5x5mg | MyBiosource | 5x5mg | EUR 1465 |
 CD134 Recombinant Protein |
|||
| 96-571 | ProSci | 0.1 mg | EUR 619.8 |
|
Description: Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5. |
|||
CD134 Recombinant Protein |
|||
| 96-572 | ProSci | 0.1 mg | EUR 619.8 |
|
Description: Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5. |
|||
 Anti-Hu CD134 PE |
|||
| 1P-152-T025 | ExBio | 25 tests | EUR 121 |
Anti-Hu CD134 PE |
|||
| 1P-152-T100 | ExBio | 100 tests | EUR 242 |
Anti-Hu CD134 PE |
|||
| MBS1800416-100Tests | MyBiosource | 100Tests | EUR 345 |
Anti-Hu CD134 PE |
|||
| MBS1800416-5x100Tests | MyBiosource | 5x100Tests | EUR 1300 |
 Anti-Hu CD134 APC |
|||
| 1A-152-T100 | ExBio | 100 tests | EUR 242 |
Anti-Hu CD134 APC |
|||
| MBS1800414-100Tests | MyBiosource | 100Tests | EUR 345 |
Anti-Hu CD134 APC |
|||
| MBS1800414-5x100Tests | MyBiosource | 5x100Tests | EUR 1300 |
, Fc fusion) OX40 (CD134), Fc fusion |
|||
| 71175 | BPS Bioscience | 100 µg | EUR 320 |
|
Description: Human secreted OX40, Fc fusion protein,_x000D_also known as Tumor Necrosis Factor_x000D_Receptor Superfamily Member 4,_x000D_TNFRSF4, and CD134, GenBank_x000D_Accession No. NM_003327, a.a. 29-216_x000D_expressed in a HEK293 cell expression_x000D_system. MW = 46.8 kDa (monomer). This_x000D_protein runs at a higher MW by SDS-PAGE_x000D_due to glycosylation. |
|||
 Anti-Hu CD134 FITC |
|||
| 1F-152-T100 | ExBio | 100 tests | EUR 198 |
Anti-Hu CD134 FITC |
|||
| MBS1800415-100Tests | MyBiosource | 100Tests | EUR 305 |
Anti-Hu CD134 FITC |
|||
| MBS1800415-5x100Tests | MyBiosource | 5x100Tests | EUR 1120 |
 MOUSE ANTI RAT CD134 |
|||
| MBS213135-01mg | MyBiosource | 0.1mg | EUR 365 |
MOUSE ANTI RAT CD134 |
|||
| MBS213135-5x01mg | MyBiosource | 5x0.1mg | EUR 1465 |
 MOUSE ANTI CAT CD134 |
|||
| MBS212886-01mg | MyBiosource | 0.1mg | EUR 390 |
MOUSE ANTI CAT CD134 |
|||
| MBS212886-5x01mg | MyBiosource | 5x0.1mg | EUR 1570 |
 RAT ANTI MOUSE CD134 |
|||
| MBS212139-025mg | MyBiosource | 0.25mg | EUR 500 |
RAT ANTI MOUSE CD134 |
|||
| MBS212139-5x025mg | MyBiosource | 5x0.25mg | EUR 2070 |
RAT ANTI MOUSE CD134 |
|||
| MBS212140-01mg | MyBiosource | 0.1mg | EUR 355 |
RAT ANTI MOUSE CD134 |
|||
| MBS212140-5x01mg | MyBiosource | 5x0.1mg | EUR 1425 |
 CD134/OX40 Rabbit pAb |
|||
| A3646 | Abclonal | 50μL | EUR 173.58 |
CD134/OX40 Rabbit pAb |
|||
| A7499 | Abclonal | 500μL | EUR 70.85 |
 Mouse CD134 ELISA Kit |
|||
| MBS824768-5x96Tests | MyBiosource | 5x96Tests | EUR 2880 |
Mouse CD134 ELISA Kit |
|||
| MBS824768-96Tests | MyBiosource | 96Tests | EUR 645 |
 Human CD134 ELISA Kit |
|||
| MBS824604-5x96Tests | MyBiosource | 5x96Tests | EUR 2880 |
Human CD134 ELISA Kit |
|||
| MBS824604-96Tests | MyBiosource | 96Tests | EUR 645 |
 Mouse Anti Human CD134 |
|||
| MBS225745-01mg | MyBiosource | 0.1mg | EUR 400 |
Mouse Anti Human CD134 |
|||
| MBS225745-5x01mg | MyBiosource | 5x0.1mg | EUR 1630 |
 (MaxLight 405)) CD134 (OX40) (MaxLight 405) |
|||
| MBS6252376-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (MaxLight 405) |
|||
| MBS6252376-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
 (MaxLight 550)) CD134 (OX40) (MaxLight 550) |
|||
| MBS6254456-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (MaxLight 550) |
|||
| MBS6254456-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
 (MaxLight 490)) CD134 (OX40) (MaxLight 490) |
|||
| MBS6253416-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (MaxLight 490) |
|||
| MBS6253416-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
 (MaxLight 650)) CD134 (OX40) (MaxLight 650) |
|||
| MBS6255496-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (MaxLight 650) |
|||
| MBS6255496-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
 (MaxLight 750)) CD134 (OX40) (MaxLight 750) |
|||
| MBS6256536-01mL | MyBiosource | 0.1(mL | EUR 995 |
CD134 (OX40) (MaxLight 750) |
|||
| MBS6256536-5x01mL | MyBiosource | 5x0.1mL | EUR 4325 |
) Rat CD134 Antibody (FITC) |
|||
| GWB-F26EE0 | GenWay Biotech | 0.1 mg | Ask for price |
) Cat CD134 Antibody (FITC) |
|||
| GWB-CF8681 | GenWay Biotech | 0.1 mg | Ask for price |
 Anti-Hu CD134 Purified |
|||
| 11-152-C025 | ExBio | 0.025 mg | EUR 71.5 |
Anti-Hu CD134 Purified |
|||
| 11-152-C100 | ExBio | 0.1 mg | EUR 143 |
) Mouse CD134 Antibody (RPE) |
|||
| GWB-61D9E3 | GenWay Biotech | 25 TESTS | Ask for price |
Mouse CD134 Antibody (RPE) |
|||
| GWB-27E029 | GenWay Biotech | 100 TESTS | Ask for price |
 anti- CD134/OX40 antibody |
|||
| FNab01422 | FN Test | 100µg | EUR 702 |
|
Description: Antibody raised against CD134/OX40 |
|||
Anti-Hu CD134 Purified |
|||
| MBS1800413-01mg | MyBiosource | 0.1mg | EUR 260 |
Anti-Hu CD134 Purified |
|||
| MBS1800413-5x01mg | MyBiosource | 5x0.1mg | EUR 930 |
-muIg-Biotin) CD134(OX40)-muIg-Biotin |
|||
| MBS666822-0025mg | MyBiosource | 0.025mg | EUR 685 |
CD134(OX40)-muIg-Biotin |
|||
| MBS666822-5x0025mg | MyBiosource | 5x0.025mg | EUR 2935 |
) Mouse CD134 Antibody (FITC) |
|||
| GWB-B38127 | GenWay Biotech | 0.025 mg | Ask for price |
Mouse CD134 Antibody (FITC) |
|||
| GWB-C19CD6 | GenWay Biotech | 0.05 mg | Ask for price |
) Rat CD134 Antibody (Biotin) |
|||
| GWB-36B1A3 | GenWay Biotech | 0.1 mg | Ask for price |
Mouse CD134 Antibody (FITC) |
|||
| GWB-22A35F | GenWay Biotech | 0.1 mg | Ask for price |
Mouse CD134 Antibody (FITC) |
|||
| GWB-23B953 | GenWay Biotech | 0.5 mg | Ask for price |
) Mouse CD134 Antibody (Biotin) |
|||
| GWB-5E597C | GenWay Biotech | 0.025 mg | Ask for price |
Mouse CD134 Antibody (Biotin) |
|||
| GWB-85C4D8 | GenWay Biotech | 0.1 mg | Ask for price |
 CD134 Recombinant Rabbit mAb |
|||
| BS49211 | Bioworld Biotech | 50 ul | EUR 398 |
|
Description: Store at -20°C. Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt. |
|||
CD134 Recombinant Rabbit mAb |
|||
| BS46791 | Bioworld Biotech | 50 ul | EUR 398 |
|
Description: Store at -20°C. Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt. |
|||
 CD134 Rat monoclonal antibody |
|||
| MB65857 | Bioworld Biotech | 50ul | EUR 275 |
|
Description: Rat IgG1 kappa. Liquid in PBS, pH 7.3, and 0.02% sodium azide. |
|||
 CD134/OX40L Receptor Antibody |
|||
| MBS5401010-01mg | MyBiosource | 0.1mg | EUR 445 |
CD134/OX40L Receptor Antibody |
|||
| MBS5401010-5x01mg | MyBiosource | 5x0.1mg | EUR 1855 |
 CD134 Antibody HRP Conjugated |
|||
| MBS9461146-01mL | MyBiosource | 0.1mL | EUR 595 |
CD134 Antibody HRP Conjugated |
|||
| MBS9461146-5x01mL | MyBiosource | 5x0.1mL | EUR 2525 |
 CD134 [OX40] Recombinant Protein |
|||
| 90-407 | ProSci | 50 ug | EUR 619.8 |
|
Description: CD134 (OX40) is a T cell activation antigen structurally belonging to a lymphocyte-specific subgroup of the nerve growth factor and tumor necrosis factor receptor superfamily, which also includes the T cell antigen CD27, B cell antigen CD40, FAS antigen and the T cell activation antigen 4-1BB. The human CD134 protein is expressed only on activated CD4 + T blasts, and its ligand has been identified as gp34. Interactions between CD134 and its ligand in vivo are necessary for the differentiation of activated B cells into highly immunoglobulin-producing cells, however not involved in other pathways of antigen-driven differentiation of B cells such as development of memory cells in the germinal centers. In addition, the CD134 and gp34 system directly mediate adhesion of activated T cells to vascular endothelial cells, and contribute to growth stimulation of the virus-infected T cells. |
|||
The lipid classification scheme is chemically based mostly and pushed by the distinct hydrophobic and hydrophilic components that compose the lipid. This structured vocabulary will facilitate the systematization of lipid biology and allow the cataloging of lipids and their properties in a means that’s appropriate with different macromolecular informationbases.